desonide/formoterol (UI030) / Korea United Pharm - LARVOL DELTA

ABC: Arformoterol/Budesonide for COVID-19 (clinicaltrials.gov) - P2; N=140; Not yet recruiting; Sponsor: Korea United Pharm. Inc.

New P2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Korea United Pharmaceutical Co., Ltd. approved the clinical trial plan for COVID-19 treatment phase 2 [Google translation] (Yonhap News Agency) - "...a clinical trial to exploratory evaluation of the efficacy and safety of the COVID-19 treatment candidate 'UI030' (ingredient name budesonide, aformoterol) applied by Korea United. It announced on the 28th that it had approved the phase 2 test plan. As a result, the number of products developed with approval for a clinical trial plan as a treatment for Corona 19 in Korea has increased to 14 items with 12 ingredients."

New P2 trial • Infectious Disease • Novel Coronavirus Disease